论文部分内容阅读
Drugs encapsulated in the nanocarriers,referred to as nanomedicines,have shown therapeutic advantages including better efficacy against resistant tumors and fewer side effects over conventional free drugs.Therefore,it is highly desirable to develop “smart” drug delivery systems(DDS)that can either passively or actively target cancer cells.Base on our recent work on single “pH-responsive supramolecular vesicles based on water-soluble pillar[6]arene(WP6)and ferrocene derivative for drug delivery”,[1] as the continued further research of supramolecular nanocarriers,we report the successful construction of two types of pillar[6]arene-based supramolecular nanocarriers based on the amphiphilic host-guest inclusion complex in water,[2] including: a)supramolecular micelles formed from WP6 and G1,which,however,gradually transformed into disordered layered structures,and b)supramolecular vesicles formed from WP6 and G2,which were stable and displayed a significant pH-and photo-responsive behavior.Significantly,MTZ drug loading and in vitro release experiments of supramolecular vesicles formed from WP6 and G2 demonstrated that MTZ could be successfully encapsulated into the vesicles,and more importantly,the resulting MTZ-loaded vesicles exhibited an excellent responsiveness and quick release of the encapsulated MTZ under acidic pH environment or upon UV stimulus.The cytotoxicity tests demonstrated that MTZ-loaded vesicles showed selective killing effect for MCF-7 cancer cells,compared with the normal NIH3T3 cells.Finally,flow cytometric analysis suggested that the molecular mechanism of the therapeutic effect of MTZ-loaded vesicles on MCF-7 cancer cells was associated with apoptosis.